Ginkgo Bioworks Holdings (DNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $622.97M
Last updated: Nov 17, 2026 at 11:03 AM ET
Ginkgo Bioworks Holdings (DNA) Stock Forecast
Analysts expect Ginkgo Bioworks Holdings (DNA) to earn -$3.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $90.07M. Of 3 analysts, 0 rate the stock Buy or Strong Buy, 1 Hold and 2 Sell or Strong Sell, for a consensus of Sell. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 4.00, inside the Sell band from 3.5 up to 4.5. Sell and Strong Sell make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 1 | 33.3% |
| Sell | 1 | 33.3% |
| Strong Sell | 1 | 33.3% |
- Consensus
- Sell
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 7.6%.
- Fiscal year ending Dec 31, 2026
- -$3.20
- EPS consensus, revenue $90.07M
- Fiscal year ending Dec 31, 2027
- -$2.90
- EPS consensus, revenue $96.90M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.20 | -$3.20 to -$3.20 | 1 | $90.07M | $90.00M to $90.20M | 3 |
| Dec 31, 2027 | -$2.90 | -$2.90 to -$2.90 | 1 | $96.90M | $84.70M to $115.00M | 3 |
Quarterly Estimates
The EPS consensus rises from -$1.27 for the quarter ending Dec 31, 2026 to -$1.05 for the quarter ending Mar 31, 2027.
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.27 | N/A | 2 | $23.03M | $22.25M to $24.05M | 4 |
| Mar 31, 2027 | -$1.05 | -$1.05 to -$1.05 | 1 | $22.10M | $19.70M to $24.10M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.42.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.20 | -$2.93 | -$3.20 | -$3.20 | -$3.42 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.90 | -$3.21 | -$3.21 | -$3.21 | -$3.21 | N/A |
Frequently Asked Questions About DNA
What is the DNA stock forecast?
Consensus analyst estimates put Ginkgo Bioworks Holdings's EPS at -$3.20 for the fiscal year ending Dec 31, 2026, on revenue of $90.07M. The consensus rating from 3 analysts is Sell.
How do analysts rate DNA stock?
Of 3 analysts covering Ginkgo Bioworks Holdings, 0 rate it Strong Buy, 0 Buy, 1 Hold, 1 Sell and 1 Strong Sell, for a consensus of Sell.
What EPS do analysts expect from DNA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.20, with estimates from -$3.20 to -$3.20 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.90, with estimates from -$2.90 to -$2.90 from 1 analyst.
What revenue do analysts expect from Ginkgo Bioworks Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $90.07M, with estimates from $90.00M to $90.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $96.90M, with estimates from $84.70M to $115.00M.
How many analysts cover DNA?
3 analysts rate Ginkgo Bioworks Holdings stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
DNA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts